Aardvark Antique Mall is the kind of place where you can literally lose yourself for hours. And I mean literally. Bring ...

Cybersecurity company SailPoint opened for trading on Thursday, returning to the markets more than two years after it went private.Maximize ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following a $94M initial public offering. Read more here.

The syndicate led by Morgan Stanley, Goldman Sachs, JP Morgan and Evercore closed the books north of 20x covered on the back of strong long-only/mutual fund demand and a 100% hit rate in investor ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Clinical-stage biopharmaceutical company Aardvark Therapeutics (AARD) priced its IPO of ~5.89M shares at $16.00 per share. All of the shares are being offered by Aardvark. The California-based startup ...

Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.

Raising $94.2 million in gross proceeds, Aardvark Therapeutics Inc. became the fifth biopharma company to list on Nasdaq so far in 2025.